DrugPatentWatch Database Preview

Ucb Inc Company Profile

Email this page to a colleague

UCB INC has forty approved drugs.

There are nineteen US patents protecting UCB INC drugs.

There are three hundred and forty-six patent family members on UCB INC drugs in fifty countries and forty-three supplementary protection certificates in fourteen countries.

International Patents:	346
US Patents:	19
Tradenames:	27
Ingredients:	22
NDAs:	40
Drug Master File Entries:	1
Patent Litigation for Ucb Inc:	See patent lawsuits for Ucb Inc

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-004	May 12, 2016		RX	Yes	No		Start Trial				Start Trial
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-004	Oct 28, 2008		RX	Yes	Yes		Start Trial				Start Trial
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;ORAL	205838-001	May 12, 2016		RX	Yes	Yes		Start Trial				Start Trial
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-004	May 12, 2016		RX	Yes	No	8,492,416	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-003	Nov 30, 1999	4,943,639*PED	Start Trial
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	6,221,392	Start Trial
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-002	Nov 30, 1999	4,837,223	Start Trial
Ucb Inc	KEPPRA	levetiracetam	TABLET;ORAL	021035-001	Nov 30, 1999	4,837,223	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Transdermal Film	1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr	➤ Subscribe	2013-11-26
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2012-10-29
➤ Subscribe	Injection	10 mg/mL, 20 mL	➤ Subscribe	2016-06-30
➤ Subscribe	Orally Disintegrating Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg	➤ Subscribe	2005-12-27
➤ Subscribe	Tablets	1000 mg	➤ Subscribe	2007-01-24
➤ Subscribe	Tablets	50 mg, 100 mg, 150 mg, and 200 mg	➤ Subscribe	2012-10-29
➤ Subscribe	Extended-release Tablets	1000 mg	➤ Subscribe	2011-01-07
➤ Subscribe	Tablets	7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg	➤ Subscribe	2004-01-15

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1033978	SZ 24/2006	Austria	Start Trial	PRODUCT NAME: ROTIGOTINE
1452524	300815	Netherlands	Start Trial	PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
1110543	08C0004	France	Start Trial	PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
1452524	C01452524/01	Switzerland	Start Trial	PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65830 06.10.2016
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.